{'fraction_non_alphanumeric': 0.022031823745410038, 'fraction_numerical': 0.0, 'mean_word_length': 5.059259259259259, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Artificial Intelligence and Cancer Drug Development.

BACKGROUND
The development of cancer drugs is among the most focused "bench to bedside activities" to improve human health. Because of the amount of data publicly available to cancer research, drug development for cancers has significantly benefited from big data and AI. In the meantime, challenges, like curating the data of low quality, remain to be resolved.


OBJECTIVE
This review focused on the recent advancements in and challenges of AI in developing cancer drugs.


METHOD
We discussed target validation, drug repositioning, de novo design, and compounds' synthetic strategies.


RESULTS AND CONCLUSION
AI can be applied to all stages during drug development, and some excellent reviews detailing the applications of AI in specific stages are available.